Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Strativa's New Drug Application For Ondansetron Orally Dissolving Film Strip Accepted By FDA
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.
generic viagra online
Millions Of People With Musculoskeletal Conditions At Risk Of Being Let Down By NHS
One-in-five (21%) primary care trusts (PCTs) do not offer "clinical assessment
News of the day
2009/043 NICE Issues Guidance To Help Healthcare Professionals Identify Child Maltreatment
NICE has issued guidance to help healthcare professionals to identify children who may have been maltreated. The guidance provides a summary of alerting features that should prompt a healthcare professional to consider, suspect or exclude child maltreatment. Child maltreatment includes neglect, physical, sexual and emotional abuse, and fabricated or induced illness.
Mental Health

Withdrawal Of Co-proxamol Linked To Reduction In Suicides And Accidental Poisonings, UK

Withdrawal of the painkiller co-proxamol from the UK market has led to a major reduction in suicides and accidental poisonings involving the drug, without an increase in deaths from other painkillers, finds research published on bmj.com today. Co-proxamol was the most commonly prescribed drug used in suicides and was responsible for 766 deaths between 1997 and 1999 in England and Wales. Concerns about large numbers of fatal poisonings led the Committee on Safety in Medicines to announce in 2005 the phasing out of co-proxamol from use in the UK by the end of 2007. Whether this initiative has been effective and reduced poisoning deaths has not been assessed. So Keith Hawton from the University of Oxford and colleagues used national records to compare the impact of the announcement of co-proxamol withdrawal on prescribing practices and deaths from co-proxamol with other painkillers mostly likely to be used instead of co-proxamol (cocodamol, codeine, codydramol, dihydrocodeine, non-steroid anti-inflammatory drugs) in England and Wales between 1998 and 2007. Findings showed a steep fall (59%), in the prescribing of co-proxamol following the announcement in 2005, accompanied by significant increases in the prescribing of other painkillers including cocodamol (up by more than 20%), paracetamol (up by more than 13%), and codeine (up by more than 8%). These changes in prescribing practices were accompanied by a 62% reduction in, or 295 fewer suicides, and 349 fewer deaths when accidental poisonings were included, without an increase in deaths involving other painkillers and prescribed drugs. This, say the authors, shows that concerns about the possible substitution of suicide method involving other painkillers were unfounded. These findings suggest that the UK initiative has been an effective measure and highlights how regulatory authorities "can have an important public health function, as has been found for measures restricting pack sizes of analgesics sold over the counter," they conclude. British Medical Journal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009